# Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Canonical URL: https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-announces-poster-on-results-from-phase-2a-trial-of-ati-2138-91f1db5b
Ticker: ACRS
Company: Aclaris Therapeutics
Source: Aclaris Therapeutics
Published: 2026-03-20 15:00 EST
## Summary

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Meeting...

## Article Body
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster on the results from its open-label Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), will be available during the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO. The poster will include results not previously reported from Aclaris’ Phase 2a trial in patients with moderate-to-severe atopic dermatitis (AD).

Electronic Poster Details:

| Title | Results from an Open-Label Phase 2 Trial of ATI-2138, an Investigational Oral Covalent Inhibitor of Interleukin-2-Inducible T Cell Kinase (ITK) And Janus Kinase 3 (JAK3), in Patients with Moderate-To-Severe Atopic Dermatitis |
| --- | --- |
| Authors | Ajay Aggarwal 1 , Aparna Kaul 1 , Loreen Stillwell 1 , Nancy McGraw 1 , Robert Mahe 1 , Rakesh Basavalingappa 1 , Emma Huff 1 , David R. Anderson 1 , Emma Guttman 2 , Joseph Monahan 1 , Neal Walker 1 |
|  | Affiliations: 1 Aclaris Therapeutics Inc.; 2 Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY |

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn .

Aclaris Therapeutics Contact:

Will Roberts Senior Vice President Corporate Communications and Investor Relations (484) 329-2125 wroberts@aclaristx.com
## Recent Company News
- 2026-05-28 12:30 EST — [Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conf-a0a234d5) — Source: Aclaris Therapeutics
- 2026-05-08 12:30 EST — [Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2026-bank-of-america-healthcare-confe-33f392b6) — Source: Aclaris Therapeutics
- 2026-05-07 10:59 EST — [Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2026-financial-results-and-provides-c-c157b37c) — Source: Aclaris Therapeutics
- 2026-04-28 10:30 EST — [Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-announces-positive-full-top-line-first-in-human-results-fro-968484cf) — Source: Aclaris Therapeutics
- 2026-04-27 20:45 EST — [Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-provide-clinical-update-on-key-biologic-and-oral-inhibit-c67a7f91) — Source: Aclaris Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)